Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Acknowledgement to reviewers95
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs73
Prognostic of recurrence and survival in poorly differentiated thyroid cancer57
Celebrating the 80th anniversary of hormone ablation for prostate cancer55
Acknowledgement to reviewers53
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients47
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas44
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing41
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications40
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells38
Targeting growth hormone in cancer: future perspectives38
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression36
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms36
Update on the genetics of paragangliomas31
Refining long-term surveillance requirements in patients with differentiated thyroid cancer31
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts30
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas30
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells28
Radioiodine treatment: an historical and future perspective28
Metabolically active brown adipose tissue in PPGL: an observational cohort study28
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation27
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet27
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells25
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination degradation24
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours24
Peptide receptor radionuclide therapy in malignant insulinoma24
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer23
Antitumor immune response is associated with favorable survival in GEP-NEN G323
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma22
Whole-exome sequencing of rectal neuroendocrine tumors22
Gender-affirming care and endocrine-related cancers22
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells22
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction21
Therapy considerations in neuroendocrine prostate cancer: what next?21
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly21
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective20
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis20
Effect of TSH levels during active surveillance of PTMC according to age20
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen19
From bench to bedside in the sella: translational developments in pituitary tumour genetics18
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring18
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis18
Immunotherapy for endocrine tumours: a clinician’s perspective18
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms17
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study17
Exploring stem cell biology in pituitary tumors and derived organoids16
Steroid profile in patients with breast cancer and in mice treated with mifepristone16
ThyroidPrint®: clinical utility for indeterminate thyroid cytology15
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer15
Acknowledgement to reviewers14
Inhibition of GATA2 in prostate cancer by a clinically available small molecule14
Acknowledgement to reviewers14
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma14
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors14
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review13
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study13
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice13
New therapeutic opportunities for women with low-grade serous ovarian cancer13
In vivo and in vitro analysis of functional effects of the SDHD H50R variant12
Cancer in Ecuadorian subjects with Laron syndrome (ELS)12
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management12
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review12
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity12
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer12
Genetic disorders and insulinoma/glucagonoma12
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus12
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid11
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms11
Sexual dimorphism in thyroid cancer: evidence from preclinical studies11
Deiodinases in thyroid tumorigenesis11
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland11
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal11
Non-pituitary GH regulation of the tissue microenvironment11
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer10
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes10
Genotype-specific development of MEN 2 constituent components in 683 RET carriers10
The science behind the relations among cancer, height, growth patterns, and growth hormone axis10
Beyond the three P’s: adrenal involvement in MEN110
Mendelian randomization to investigate the link between TSH and thyroid cancer10
Genetic variants and down-regulation of CACNA1H in pheochromocytoma10
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis10
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma10
In memoriam: Charis Eng MD PhD (1962–2024)10
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane10
MicroRNAs as regulators of tumor metabolism10
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer9
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer9
mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs9
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover9
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center9
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms9
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors9
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer9
Surrogate molecular classification of LAR breast cancer in routine workflow9
Precocious puberty due to intracranial germ cell tumors: a case–control study9
Risk factors for intraoperative complications in pheochromocytomas9
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading9
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L29
Management of high-grade neuroendocrine neoplasms: impact of functional imaging9
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma9
0.11688995361328